AR083751A1 - Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer - Google Patents

Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer

Info

Publication number
AR083751A1
AR083751A1 ARP110104105A ARP110104105A AR083751A1 AR 083751 A1 AR083751 A1 AR 083751A1 AR P110104105 A ARP110104105 A AR P110104105A AR P110104105 A ARP110104105 A AR P110104105A AR 083751 A1 AR083751 A1 AR 083751A1
Authority
AR
Argentina
Prior art keywords
treatment
pirrolo
piridine
cancer
derivatives
Prior art date
Application number
ARP110104105A
Other languages
English (en)
Spanish (es)
Inventor
Heinrich Timo Dr
Wucherer-Plietker Margarita Dra
Buchstaller Hans-Peter Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR083751A1 publication Critical patent/AR083751A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP110104105A 2010-11-05 2011-11-04 Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer AR083751A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010050558A DE102010050558A1 (de) 2010-11-05 2010-11-05 1H-Pyrrolo[2,3-b]pyridinderivate

Publications (1)

Publication Number Publication Date
AR083751A1 true AR083751A1 (es) 2013-03-20

Family

ID=44897681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104105A AR083751A1 (es) 2010-11-05 2011-11-04 Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer

Country Status (11)

Country Link
US (3) US8664236B2 (enExample)
EP (1) EP2635574B1 (enExample)
JP (1) JP5891234B2 (enExample)
CN (1) CN103180320B (enExample)
AR (1) AR083751A1 (enExample)
AU (1) AU2011325480B2 (enExample)
CA (1) CA2816896C (enExample)
DE (1) DE102010050558A1 (enExample)
ES (1) ES2525172T3 (enExample)
IL (1) IL226095A (enExample)
WO (1) WO2012059172A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
AU2013263420A1 (en) * 2012-05-15 2015-01-22 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic Hsp90
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2017184549A1 (en) * 2016-04-18 2017-10-26 Innov17 Llc Pyrrolopyridine retinoic acid receptor-related orphan receptor modulators and uses thereof
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
WO2022203399A1 (ko) * 2021-03-26 2022-09-29 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
US20100267707A1 (en) * 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate

Also Published As

Publication number Publication date
EP2635574B1 (de) 2014-09-10
CA2816896C (en) 2019-01-08
DE102010050558A1 (de) 2012-05-10
IL226095A0 (en) 2013-06-27
CN103180320A (zh) 2013-06-26
EP2635574A1 (de) 2013-09-11
CN103180320B (zh) 2015-10-07
WO2012059172A1 (de) 2012-05-10
US20140100221A1 (en) 2014-04-10
US8895575B2 (en) 2014-11-25
AU2011325480B2 (en) 2015-03-26
JP5891234B2 (ja) 2016-03-22
US20130231519A1 (en) 2013-09-05
CA2816896A1 (en) 2012-05-10
IL226095A (en) 2016-03-31
ES2525172T3 (es) 2014-12-18
AU2011325480A1 (en) 2013-05-02
US8664236B2 (en) 2014-03-04
JP2013541565A (ja) 2013-11-14
US9238651B2 (en) 2016-01-19
US20140371215A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
CY1121799T1 (el) Παραγωγα πυριμιδο[4,5-β]ινδολης και χρηση εξ αυτων στην επεκταση των αιμοποιητικων αρχεγονων κυτταρων
CR20130210A (es) DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK
AR067505A1 (es) Derivados de pirimidinil-piridazinona
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BR112013024122A2 (pt) compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
CU23550B7 (es) Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa
CU20140110A7 (es) Compuestos heterocíclicos como inhibidores de mek
CL2011000917A1 (es) Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias.
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
NI201500054A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY31141A1 (es) Compuestos de piperidina y sus usos
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal